Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
PPTA Executive Summary of FDA’s U.S. Immunoglobulin Utilization Study Report
The CBER Surveillance Program BEST Initiative recently posted its Assessment of Immune Globulin Utilization in Commercially insured and Medicare Populations study report. The aim of the study is to provide a better picture of the evolution of Ig use over a 10-year longitudinal period in the context of emerging scientific evidence and clinical trends. PPTA developed an Executive Summary of the study report, highlighting key observations, findings, and conclusions.
All
PPTA statements
PPTA Executive Summary of FDA’s U.S. Immunoglobulin Utilization Study Report
The CBER Surveillance Program BEST Initiative recently posted its Assessment of Immune Globulin Utilization in Commercially insured and Medicare Populations study report. The aim of the study is to provide a better picture of the evolution of Ig use over a 10-year longitudinal period in the context of emerging scientific evidence and clinical trends. PPTA developed an Executive Summary of the study report, highlighting key observations, findings, and conclusions.
All
PPTA statements
Regulatory Policy
PPTA advocates for rational regulatory policy through active dialogue with regulatory authorities throughout the world. PPTA supports regulatory policies that help ensure the safety and quality of plasma protein therapies. Regulatory staff respond to policy documents and issues, as needed, and are actively engaged on issues ranging from the collection of source plasma through the manufacture of therapies that are administered to patients. As regulations may differ in various parts of the world, PPTA also works to promote harmonization among them, where beneficial.
All
Safety and quality
Regulatory Policy
PPTA advocates for rational regulatory policy through active dialogue with regulatory authorities throughout the world. PPTA supports regulatory policies that help ensure the safety and quality of plasma protein therapies. Regulatory staff respond to policy documents and issues, as needed, and are actively engaged on issues ranging from the collection of source plasma through the manufacture of therapies that are administered to patients. As regulations may differ in various parts of the world, PPTA also works to promote harmonization among them, where beneficial.
All
Safety and quality
Pathogen Safety
PPTA and its member companies adhere rigorously to international regulatory requirements and industry voluntary standards through PPTA's IQPP and QSEAL programs to ensure that patients have access to safe state-of-the-art therapies for the treatment of often life-threatening diseases.
All
Safety and quality
Pathogen Safety
PPTA and its member companies adhere rigorously to international regulatory requirements and industry voluntary standards through PPTA's IQPP and QSEAL programs to ensure that patients have access to safe state-of-the-art therapies for the treatment of often life-threatening diseases.
All
Safety and quality
International Quality Plasma Program (IQPP)
"PPTA's voluntary standards program provides global leadership for the plasma protein industry's goal of continuous improvement with a focus on safety and quality from the donor to the patient. The Standards Program will be transparent, credible, innovative, and responsive to stakeholder and industry needs." - Mission Statement, PPTA Voluntary Standards Program
All
Safety and quality
International Quality Plasma Program (IQPP)
"PPTA's voluntary standards program provides global leadership for the plasma protein industry's goal of continuous improvement with a focus on safety and quality from the donor to the patient. The Standards Program will be transparent, credible, innovative, and responsive to stakeholder and industry needs." - Mission Statement, PPTA Voluntary Standards Program
All
Safety and quality
No results found